The RECOVERY study has been looking into a series of therapeutic drugs to determine whether they will improve the outcome in patients hospitalised with COVID-19.
Specifically, researchers have been looking at Kaletra, a HIV medication; Tocilizumab, a monoclonal antibody against IL-6; Hydroxychloroquine; Azithromycin; and low-dose Dexamethasone as possible treatments.
Dr Nick Maskell, speaks further on the aims of the RECOVERY study at North Bristol NHS Trust:
(Video taken in March 2020, prior to trial results)
Hello, I'm Nick Maskell, one of the Chest Consultants at North Bristol NHS Trust, and the local Principal Investigator for the RECOVERY study.
This is a large randomised control trial which is currently recruiting to over 140 hospitals across the UK.
The RECOVERY study is looking at five therapeutic drugs to see if any of these improve the outcome in patients hospitalised with COVID-19. These drugs are Kaletra, a HIV medication; Tocilizumab, a monoclonal antibody against IL-6; Hydroxychloroquine; Azithromycin; and low-dose Dexamethasone.
Currently we've recruited over 80 patients in the Trust to the study, and nationally over 10,000.
I would like to thank all the patients that have participated in this study and the fantastic research team that have helped recruit these patients.
Take Part in Research
Become one of the thousands of people taking part in research every day within the NHS.